Rare EGFRm NSCLC: More First-Line Options Emerge.

Next-generation tyrosine kinase inhibitor sunvozertinib shows superior efficacy over chemotherapy as a first-line treatment for EGFR exon 20 insertion non-small cell lung cancer in the phase III WU-KONG28 trial.

• Why it matters: Expanding first-line options for rare EGFR mutations in non-small cell lung cancer addresses a critical gap, as traditional therapies often have limited effectiveness for these patients.
• What they did: The study evaluated sunvozertinib in a large patient cohort, demonstrating its potential as an effective initial therapy compared to standard chemotherapy, with promising results.
• The result: This finding suggests sunvozertinib could become a new standard for first-line treatment, offering improved outcomes for patients with EGFR exon 20 insertions and broadening therapeutic choices.